Nature: Newly Discovered Special Neurons - Glutamatergic Astrocytes
Researchers at the University of Lausanne in Switzerland have published a study in the journal Nature titled "Specialized Astrocytes Mediate Glutamatergic Gliotransmission in the CNS."
These specialized cells play a vital role in enhancing memory function, participating in motor control, and safeguarding the central nervous system (CNS), shedding new light on the intricate role of astrocytes in the physiology and pathology of the CNS. They also provide potential targets for the treatment of CNS diseases such as epilepsy, Alzheimer's, Parkinson's, and more.
Multi-modal astrocyte-neuron communication controls the assembly and function of brain circuits. For example, by rapidly releasing glutamate, astrocytes can regulate synaptic network excitability, plasticity, and synchronous activity, but they also contribute to synaptic network dysregulation in neuropsychiatric disorders. For astrocytes to engage in information exchange through fast glutamate release, they must possess Ca2+-dependent exocytotic machinery similar to neurons. However, the existence of this mechanism has been in doubt due to inconsistent research data and a lack of direct supporting evidence.
To confirm whether astrocytes can release neurotransmitters like neurons, the researchers first closely examined the gene expression profile of astrocytes to identify the mechanisms required for the rapid secretion of glutamate, the primary neurotransmitter used by neurons.
Using single-cell transcriptomics, the research team identified nine molecularly distinct subtypes of hippocampal astrocytes, with one particular subtype known as glutamatergic astrocytes, expressing specific synaptic-like glutamate release mechanisms and located at different hippocampal sites. This subtype of astrocytes exhibited the transcription of vesicular glutamate transporter 1 (VGLUT1), a protein responsible for selectively loading glutamate into synaptic vesicles and promoting its release in the synaptic cleft. The study also found that these cells contained other essential proteins for glutamatergic vesicle function and rapid information exchange with other cells.
Fig. 2: Identification of a subpopulation of glutamatergic astrocytes in the mouse and human hippocampus. (From Nature, 2023, doi:10.1038/s41586-023-06502 )
Subsequently, the researchers attempted to confirm the functionality of these unique glutamatergic astrocytes, specifically, whether they could release glutamate at a rate comparable to synaptic transmission. To do this, they used GluSnFR-basedin vivo and in vitro imaging techniques to visualize glutamate vesicle release in brain tissue and live mice.
The results revealed that glutamatergic astrocytes responded to selective stimulation by rapidly releasing glutamate, occurring in spatially segregated regions of the cells, similar to neuronal synapses. Furthermore, glutamate release impacted synaptic transmission and regulated neuronal circuits, as the research team demonstrated by inhibiting the expression of VGLUT in these cells.
The study also found a connection between these glutamatergic astrocytes and brain diseases. By specifically knocking out VGLUT1 in these cells, the research team confirmed the impact of these cells on memory consolidation and observed their association with pathology, such as exacerbating seizures.
Lastly, the research suggests that glutamatergic astrocytes are involved in regulating brain circuits related to motor control, potentially providing new therapeutic targets for Parkinson's disease. The team's future studies will further explore the potential protective role of this cell type in memory loss associated with Alzheimer's disease and its role in other brain regions and diseases.
More information: de Ceglia, Roberta, et al. "Specialized astrocytes mediate glutamatergic gliotransmission in the CNS." Nature (2023): 1-10.
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P1686) (Cat#: NRP-0422-P1686)
- iNeuMab™ Mouse Anti-EFNB2 Monoclonal Antibody (CBP1159) (Cat#: NAB-0720-Z4396)
- iNeuMab™ Anti-SEZ6 Antibody (NRP-0422-P517) (Cat#: NRP-0422-P517)
- Mouse Anti-SCN5A Monoclonal Antibody (CBP708) (Cat#: NAB-0720-Z2720)
- iNeuMab™ Anti-ApoC3 BBB Shuttle Antibody (NRZP-1022-ZP3505) (Cat#: NRZP-1022-ZP3505)
- iNeuMab™ Anti-Amyloid Beta 1-15 Antibody (NRP-0422-P867) (Cat#: NRP-0422-P867)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P2293) (Cat#: NRP-0422-P2293)
- iNeuMab™ Anti-F-Spondin/SPON1 Antibody, Clone 3F4 (Cat#: NRZP-0822-ZP4740)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P1760) (Cat#: NRP-0422-P1760)
- iNeuMab™ Anti-Integrin αvβ8 BBB Shuttle Antibody (NRZP-1222-ZP1218) (Cat#: NRZP-1222-ZP1218)
- Green Fluorescent Alpha-synuclein Cell Line (Cat#: NCL2110P209)
- Human Brain Microvascular Endothelial Cells (Cat#: NCL-2103-P133)
- Rat Muller Cell (Cat#: NCL2110P040)
- Green Fluorescent BACE1 Cell Lines (Cat#: NCL2110P214)
- Rat Schwann Cells RSC96, Immortalized (Cat#: NCL-2108P21)
- Rat Immortalized Retinal Muller Cell Line rMC-1 (Cat#: NCL-2106-S93)
- Mouse Midbrain Dopaminergic Neuron Cell MN9D (Cat#: NCL2110P059)
- iNeu™ Human Neural Stem Cell Line (Cat#: NCL200552ZP)
- Human Microglia Cell Line HMC3, Immortalized (Cat#: NCL-2108P38)
- iNeu™ Human Schwann Cell (Cat#: NCL-2103-P63)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- AAV2/9-hEF1a-fDIO-eNpHR 3.0-mCherry-WPRE-pA (Cat#: NTA-2012-ZP78)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein (Cat#: NRZP-0423-ZP506)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP501)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)